Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug showdown: which works best when kidneys also fail?

NCT ID NCT07186062

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 60 adults with acute decompensated heart failure and kidney impairment. Researchers compared three intravenous heart medications—levosimendan, dobutamine, and milrinone—to see which one improved heart and kidney function best. The goal was to find the most effective option for managing this difficult combination of conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Levosimendan, dobutamine, and milrinone (heart-failure medications given intravenously)
What this could lead to
If one drug proves clearly better, it could guide doctors to choose the most effective treatment for heart failure patients who also have kidney issues.
What could go wrong
This is a small, completed study (60 people) that compares existing drugs, so it won't produce a new treatment. Results may not apply to all patients, and each drug carries risks like low blood pressure or heart rhythm problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jun 2022

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult (\>18 years old) patients with ADHF (LVEF ≤ 40% documented prior to enrollment) admitted to the ICU with renal impairment (estimated GFR between 30 and 60 mL/min/1.73 m², calculated using the Modification of Diet in Renal Disease Study equation (MDRD equation) \[10\] and require inotropic support.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (\>18 years old) patients with ADHF (LVEF ≤ 40% documented prior to enrollment) admitted to the ICU with renal impairment (estimated GFR between 30 and 60 mL/min/1.73 m², calculated using the Modification of Diet in Renal Disease Study equation (MDRD equation)) and require inotropic support. Exclusion Criteria: Cases were excluded from the study if they met any of the following criteria: * Age younger than 18 years * Untreated acute HF * Resting heart rate exceeding 120 beats per minute * Recent MI or acute coronary syndrome within the previous two months * Diagnosed pulmonary embolism * Structural cardiac conditions * Known history of kidney disease diagnosed prior to HF * Administration of contrast agents or nephrotoxic drugs within the previous seven days * Severe liver dysfunction (Child C) * Active acute inflammatory or infectious diseases.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute decompensated heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardio-renal syndrome congestive heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute decompensated heart failure (ADHF) Cardiorenal syndrome (CRS)

Contacts and locations

Locations

  • faculty of medicine Ain shams University

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.